<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04673630</url>
  </required_header>
  <id_info>
    <org_study_id>D5180C00025</org_study_id>
    <nct_id>NCT04673630</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Pharmacokinetics of Tezepelumab in Children With Asthma</brief_title>
  <acronym>TRAILHEAD</acronym>
  <official_title>A Phase I, Open-label Study to Evaluate the Pharmacokinetics of Tezepelumab in Children ≥ 5 to 11 Years of Age With Mild, Moderate, or Severe Asthma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>AstraZeneca</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the pharmacokinetic (PK) profile of a single subcutaneous (SC) dose&#xD;
      of tezepelumab in children aged ≥ 5 to 11 years with asthma.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 23, 2021</start_date>
  <completion_date type="Anticipated">June 22, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 22, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>No masking is used. All involved know the identity of the intervention assignment.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Maximum serum concentration (cmax)</measure>
    <time_frame>Baseline Day 1 and on Days 3, 7, 11, 15, 29, 57 and 85</time_frame>
    <description>To describe the pharmacokinetics (PK) of Tezepelumab administered subcutaneously (SC) in children ≥ 5 to 11 years of age with mild, moderate, or severe asthma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Time to reach Cmax (tmax)</measure>
    <time_frame>Baseline Day 1 and on Days 3, 7, 11, 15, 29, 57 and 85</time_frame>
    <description>To describe the pharmacokinetics (PK) of Tezepelumab administered subcutaneously (SC) in children ≥ 5 to 11 years of age with mild, moderate, or severe asthma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Area under the concentration-time curve (AUC)</measure>
    <time_frame>Baseline Day 1 and on Days 3, 7, 11, 15, 29, 57 and 85</time_frame>
    <description>To describe the pharmacokinetics (PK) of Tezepelumab administered subcutaneously (SC) in children ≥ 5 to 11 years of age with mild, moderate, or severe asthma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Terminal phase elimination half-life (t1/2)</measure>
    <time_frame>Baseline Day 1 and on Days 3, 7, 11, 15, 29, 57 and 85</time_frame>
    <description>To describe the pharmacokinetics (PK) of Tezepelumab administered subcutaneously (SC) in children ≥ 5 to 11 years of age with mild, moderate, or severe asthma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent clearance (CL/F)</measure>
    <time_frame>Baseline Day 1 and on Days 3, 7, 11, 15, 29, 57 and 85</time_frame>
    <description>To describe the pharmacokinetics (PK) of Tezepelumab administered subcutaneously (SC) in children ≥ 5 to 11 years of age with mild, moderate, or severe asthma.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent steady-state volume of distribution (Vss/F)</measure>
    <time_frame>Baseline Day 1 and on Days 3, 7, 11, 15, 29, 57 and 85</time_frame>
    <description>To describe the pharmacokinetics (PK) of Tezepelumab administered subcutaneously (SC) in children ≥ 5 to 11 years of age with mild, moderate, or severe asthma.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Total number of subjects in the study that tested positive for anti-drug antibodies (ADA) to Tezepelumab</measure>
    <time_frame>Baseline Day 1 and on Days 29 and 85</time_frame>
    <description>To evaluate the immunogenicity of tezepelumab.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">14</enrollment>
  <condition>Asthma</condition>
  <arm_group>
    <arm_group_label>Tezepelumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Tezepelumab subcutaneous injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Tezepelumab</intervention_name>
    <description>Single dose subcutaneous injection</description>
    <arm_group_label>Tezepelumab</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Written informed consent and written informed assent and any locally required&#xD;
             authorisation obtained from the subject and legal representative prior to any study&#xD;
             related procedure taking place.&#xD;
&#xD;
          -  Age 5 to 11 years (inclusive) at Visit 1 and Visit 2 (Day 1). Type of Subject and&#xD;
             Disease Characteristics&#xD;
&#xD;
          -  Documented physician diagnosed asthma for at least 6 months prior to Visit 1.&#xD;
&#xD;
          -  Documented treatment with total daily dose of either low, medium, or high dose ICS for&#xD;
             at least 6 months, as described in Step 2 to Step 4 of GINA guidelines (GINA 2020)&#xD;
             with stable dose for at least 3 months prior to Visit 1.&#xD;
&#xD;
          -  Pre bronchodilator (BD) FEV1 of ≥ 50% of predicted normal value at Visit 1&#xD;
&#xD;
          -  Body weight ≥ 16 kg at Visit 1 and Visit 2 (Day 1).&#xD;
&#xD;
          -  Body mass index for age at both screening and Day 1 that is between 5th and 95th&#xD;
             percentile (Centers for Disease Control Growth Charts).&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  History of any clinically significant disease or disorder other than asthma which, in&#xD;
             the opinion of the Investigator, may either put the subject at risk because of&#xD;
             participation in the study, or influence the results or the subject's ability to&#xD;
             participate in the study.&#xD;
&#xD;
          -  History of a deterioration in asthma or asthma exacerbation that required a burst of&#xD;
             systemic corticosteroids within 3 months of Visit 1, up to and including Visit 2 (Day&#xD;
             1).&#xD;
&#xD;
          -  History of hospitalisation (overnight admission) for asthma within 6 months of Visit&#xD;
             1, up to and including Visit 2 (Day 1).&#xD;
&#xD;
          -  History of a life threatening asthma exacerbation requiring intubation or mechanical&#xD;
             ventilation.&#xD;
&#xD;
          -  History of systemic corticosteroid use for the maintenance treatment of asthma within&#xD;
             3 months of Visit 1, up to and including Visit 2 (Day 1) and discouraged until EOS.&#xD;
&#xD;
          -  History of cancer.&#xD;
&#xD;
          -  History of hypersensitivity or anaphylactic reaction to any biologic therapy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>5 Years</minimum_age>
    <maximum_age>11 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonathan Grigg, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal London Hospital, United Kingdom</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>AstraZeneca Clinical Study Information Center</last_name>
    <phone>1-877-240-9479</phone>
    <email>information.center@astrazeneca.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bradford</city>
        <zip>BD9 6RJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Bristol</city>
        <zip>BS2 8BJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Glasgow</city>
        <zip>G51 4TF</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>E1 1BB</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>London</city>
        <zip>SE5 9RS</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>December 2, 2020</study_first_submitted>
  <study_first_submitted_qc>December 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 17, 2020</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Mild asthma</keyword>
  <keyword>Moderate asthma</keyword>
  <keyword>Severe asthma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Asthma</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure&#xD;
Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.</ipd_description>
    <ipd_time_frame>AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_time_frame>
    <ipd_access_criteria>When a request has been approved AstraZeneca will provide access to the de-identified individual patient-level data in an approved sponsored tool . Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.</ipd_access_criteria>
    <ipd_url>https://astrazenecagroup-dt.pharmacm.com/DT/Home</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

